Abstract
Cystic fibrosis (CF) is a genetic disease affecting mucosal secretions. Most patients experience digestive symptoms, but the mechanisms are incompletely understood. Here we explore causes and consequences of slower gastrointestinal transit using magnetic resonance imaging (MRI).
Twelve people with CF and 12 healthy controls, matched for age and gender, underwent MRI scans both fasted and after standardised meals over a period of 6.5 hours. Images were assessed for small bowel motility, longitudinal relaxation time (T1) of ascending colon chyme, chyme texture and appearance of the colon wall.
Small bowel motility scores were significantly lower in CF than in healthy controls in the fasting state (CF median 40 arbitrary units IQR [31, 46] vs Control 86 a.u. [52, 106], P=0.034). This difference was less pronounced postprandially. Furthermore, ascending colon chyme T1 was lower in CF than in controls (CF 0.59 s [0.38, 0.77] vs Control 0.79 s [0.55, 1.31], P=0.010). The difference in texture between small bowel and colon chyme, seen in health, was diminished in CF (difference in Haralick contrast 0.90 a.u. [0.38, 1.67] vs Control 2.11 a.u. [0.71, 3.30], P=0.010). Ascending colon mucosa in CF participants had an abnormal appearance compared to controls (Score 1-3, CF 2 [1, 3] vs Controls 1 [1, 1], P=0.019).
Reduced small bowel motility and water content of ascending colon chyme are consistent with slower transit and constipation. MRI provides unique insights into chyme texture in the small bowel (suggesting bacterial overgrowth) and the appearance of the colon mucosa (suggesting altered mucus) in CF.
Key point summary
- People with cystic fibrosis (CF) have intrusive digestive symptoms and severe gut complications, but mechanisms are incompletely understood.
- In this study, 12 people with CF were compared to healthy controls, undergoing repeated MRI scans before and after standardised meals.
- Fasted small bowel motility is reduced in people with CF, consistent with slower transit. In addition, a reduced colonic chyme water content and abnormal appearance of small bowel and colonic chyme as well as colonic mucosa suggest small bowel bacterial overgrowth, fat malabsorption and abnormal mucus production
- These MRI outcomes hold promise in the assessment of therapeutic interventions.
Competing Interest Statement
ND, CH, LM, IS & PG have nothing to disclose. CN and GM report grants and speaker honorarium from Vertex, outside the submitted work. RS reports grants from Zespri International Ltd and Sanofi- Aventis, as well as lecturing fees from Menarini and Alfawasserman, outside the submitted work. AM is the CEO of Motilent Limited, a medical imaging analysis company. AS reports grants from Vertex, as well as speaker honoraria and expenses from Teva and Vertex, outside the submitted work. In addition, AS has a patent issued 'Alkyl quinolones as biomarkers of Pseudomonas aeruginosa infection and uses thereof'.
Clinical Trial
NCT03566550
Funding Statement
Funding for the Gut Imaging for Function and Transit in CF (GIFT-CF) study was received from the Cystic Fibrosis Foundation (Clinical Pilot and Feasibility Award SMYTH18A0-I), the Cystic Fibrosis Trust (VIA 061), and the National Institute for Health Research Nottingham Biomedical Research Centre. The views expressed are those of the authors and not necessarily those of the National Health Service (NHS), the NIHR, or the Department of Health and Social Care.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the UK National Research Ethics Committee (18/WM/0242).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data that support the findings of this study are available from the corresponding author upon reasonable request.
